Lonza Group Ag (OTCMKTS:LZAGY) Sees Large Decline in Short Interest

Lonza Group Ag (OTCMKTS:LZAGY) was the recipient of a significant decrease in short interest during the month of February. As of February 13th, there was short interest totaling 8,172 shares, a decrease of 62.7% from the January 29th total of 21,908 shares. Based on an average daily trading volume, of 428,761 shares, the short-interest ratio is currently 0.0 days. Approximately 0.0% of the company’s stock are short sold. Approximately 0.0% of the company’s stock are short sold. Based on an average daily trading volume, of 428,761 shares, the short-interest ratio is currently 0.0 days.

Lonza Group Stock Performance

Shares of Lonza Group stock opened at $67.93 on Thursday. Lonza Group has a 12-month low of $55.57 and a 12-month high of $73.85. The company has a quick ratio of 1.77, a current ratio of 2.24 and a debt-to-equity ratio of 0.42. The stock has a 50 day moving average price of $68.40 and a two-hundred day moving average price of $68.44.

Analyst Ratings Changes

A number of analysts have issued reports on the stock. Royal Bank Of Canada upgraded shares of Lonza Group from a “hold” rating to a “moderate buy” rating in a research note on Wednesday, February 11th. Zacks Research downgraded shares of Lonza Group from a “hold” rating to a “strong sell” rating in a report on Wednesday, February 4th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold”.

About Lonza Group

Lonza Group is a Swiss multinational life sciences company that provides products and services to the pharmaceutical, biotech and specialty ingredients markets. Headquartered in Switzerland, the company operates globally with manufacturing and research facilities across Europe, North America and Asia, serving customers involved in drug discovery, development and commercial production. Lonza’s client base ranges from large pharmaceutical firms to emerging biotech companies and manufacturers of consumer health and specialty chemical products.

The company’s core activities center on contract development and manufacturing (CDMO) for small molecules and biologics, including process development, clinical and commercial-scale manufacturing, and fill–finish services.